Lv4
572 积分 2023-09-19 加入
Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn’s Disease
4小时前
待确认
Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan
4小时前
待确认
Dual-targeted therapy for the management of refractory Crohn’s disease: a retrospective cohort study
4小时前
待确认
Efficacy and safety in the short-to-intermediate term of advanced combination therapy with upadacitinib for refractory Crohn’s disease: real-world evidence from eastern China
4小时前
待确认
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
4小时前
求助中
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
4小时前
待确认
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
1天前
待确认
Histological remission as a reliable predictor of clinical outcomes in patients with ulcerative colitis after conventional therapy: a 5-year analysis
1天前
待确认
Dual Biologic or Small Molecule Therapy in Pediatric Inflammatory Bowel Disease: A Single Center Experience
10天前
已完结
皖公网安备34019202002308
